SCHEMBL5954470

SCHEMBL5954470

C[C@@H]1C(=O)N(c2ccccc2)C(=S)N1c1ccc(Oc2ccccc2)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MGLL Q99685 1/20 0.49
LMNA P02545 1/20 0.48
ALDH1A1 P00352 5/20 0.43
MAPT P10636 4/20 0.43
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NTRK1 P04629 1/20 0.41
IGF1R P08069 1/20 0.41
FGFR1 P11362 1/20 0.41
NTRK3 Q16288 1/20 0.41
NTRK2 Q16620 1/20 0.41
MAPK1 P28482 2/20 0.40
ALOX15 P16050 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
GAA P10253 1/20 0.40
ABCB1 P08183 2/20 0.39
PLCG1 P19174 1/20 0.39
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5954383 1.00 MGLL (0.49) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5954389 1.00 MGLL (0.49) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5954387 1.00 MGLL (0.49) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5955006 0.99 MGLL (0.50) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5954469 0.93 ABCB1 (0.47) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5955343 0.93 ABCB1 (0.47) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5954435 0.92 CDK2 (0.44) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5955239 0.92 CDK2 (0.44) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5954503 0.92 LTA4H (0.45) MGLLLMNAALDH1A1MAPTKMT2A
SCHEMBL5954807 0.92 ALDH1A1 (0.42) MGLLLMNAALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LABORATOIRES FOURNIER S.A. (FR) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060025589-A1 2-Thiohydantoine derivative compounds and use thereof for the treatment of diabetes LIPC, CYP4F2, SLC5A2 MGLL 432/4885LMNA 3718/4885ALDH1A1 452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.